Advanced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Alicia C. Lenzen

Pediatric Hematology Oncology
225 E Chicago Ave # 30, 
Chicago, IL 
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
225 E Chicago Ave # 30, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alicia Lenzen is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Lenzen is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Glioma, Medulloblastoma, Diffuse Midline Glioma H3 K27M-Mutant, and Optic Glioma.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Diffuse Midline Glioma H3 K27M-Mutant.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

225 E Chicago Ave # 30, Chicago, IL 60611

Additional Areas of Focus

Dr. Lenzen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 1
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Procedure, Drug
Study Drug: Savolitinib
Study Phase: Phase 1
View 3 Less Clinical Trials

16 Total Publications

A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
Journal: Neuro-oncology
Published: December 19, 2024
Similar Doctors
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andres E. Morales
Pediatric Hematology Oncology
Distinguished in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andres E. Morales
Pediatric Hematology Oncology
5841 S Maryland Ave, Mc 4060, 
Chicago, IL 
 (7.5 miles away)
773-702-6808
Languages Spoken:
English

Andres Morales is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Morales is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Cerebral Ventricle Cancer, and Glioma.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ashley S. Plant
Pediatric Hematology Oncology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ashley S. Plant
Pediatric Hematology Oncology
225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
800-543-7362
Languages Spoken:
English
See accepted insurances

Ashley Plant is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Plant is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Medulloblastoma, Optic Glioma, and Glioma.

Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Elaine R. Morgan
Pediatric Hematology Oncology
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Elaine R. Morgan
Pediatric Hematology Oncology
225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-4090
Languages Spoken:
English
See accepted insurances

Elaine Morgan is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Morgan is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Childhood Acute Myeloid Leukemia, Febrile Neutropenia, and Leukemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lenzen's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile